Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or Refractory Acute Lymphoblastic Leukemia

• ClinicalTrials.gov Identifier: NCT02030847
• Recruitment Status: Completed
• First Posted: January 9, 2014
• Results First Posted: May 24, 2019
• Last Update Posted: August 30, 2019
• Sponsor: University of Pennsylvania
• Information provided by (Responsible Party): University of Pennsylvania

Study Description

Brief Summary:

This is a single center, single arm, open-label phase II study to determine the efficacy and safety of a single infusion of autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR and 4-1BB (TCR/4-1BB) co-stimulatory domains (referred to as CART-19 cells) in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia. Inclusion criteria are designed to include adult patients aged greater than 18 with B cell ALL, relapsed or refractory, with no available curative treatment options (such as autologous or allogeneic stem cell transplantation) who have limited prognosis (greater than 12 weeks survival expectancy) with currently available therapies. The study product is CART-19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCR:41BB administered by a single i.v. infusion of 1 to 5 x 108 transduced CAR T cells.

Condition or disease	Intervention/treatment	Phase
Patients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment Options	Biological: CART-19	Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 42 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Phase II Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCR and 4-1BB Signaling Domains in Patients With Chemotherapy Resistant or RefractoryAcute Lymphoblastic Leukemia
• Actual Study Start Date: February 27, 2014
• Actual Primary Completion Date: April 26, 2018
• Actual Study Completion Date: April 26, 2018

Arms and Interventions

Arm

Intervention/treatment

Experimental: Arm1; phase II study to determine the efficacy and safety of a single infusion of autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as "CART-19" cells) in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Biological: CART-19; CART-19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCR:41BB administered by a single i.v. infusion of 1 to 5 x 10^8 transduced CAR T cells; Biological: CART-19; As of June 2014, dose was reduced to a single dose of 1-5x10^7 CART-19 cells.; Biological: CART-19; In the protocol amendment in November 2014, the dose remained 1-5 x 10^7 CART-19 cells, but was revised to be administered via split dosing: 10% on Day 1, 30% on Day 2, 60% on Day 3.; Biological: CART-19; In the protocol amendment in May 2015, the dose was changed to 1-5 x 10^8 CART-19 cells administered via split dosing: 10% on Day 1 (1-5x10^7), 30% on Day 2 (3x10^7-1.5x10^8), 60% on Day 3 (6x10^7-3x10^8).

Outcome Measures

Primary Outcome Measures :

1. Overall Complete Remission Rate at Day 28 After CART-19 Therapy [ Time Frame: 28 Days ]

   Overall Complete Remission Rate (ORR) which includes complete remission (CR) and CR with incomplete blood count recovery (CRi) at Day 28.

   Overall Complete Remission Rate = CR+ CRi

Secondary Outcome Measures :

1. Best Overall Response [ Time Frame: from the start of the treatment until death, last follow up, relapse or start of new anticancer therapy, whichever comes first, assessed up to 12 months ]
   For the secondary efficacy objectives for this study, the number of patients were computed with a best overall disease response of CR or CRi, where the best overall disease response is defined as the best disease response recorded from the start of the treatment until death, last follow up, relapse or start of new anticancer therapy, whichever comes first.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria

• Signed informed consent form must be obtained prior to any study procedure

• Relapsed or refractory B-cell ALL

  1. 1st or greater BM relapse OR
  2. Any marrow relapse after allogeneic HSCT and > 100 days from transplant OR
  3. For patients with refractory disease:

  i. < 60 years old that have not achieved a CR after > 2 or more chemotherapy regimens ii. >60 years old that have not achieved a CR after 1 prior chemotherapy regimen d. Patients with Ph+ ALL are eligible if they have failed tyrosine kinase inhibitor therapy

• Documentation of CD19 tumor expression in bone marrow or peripheral blood by flow cytometry within 3 months of screening.

• Adequate organ function defined as:

  1. Creatinine < 1.6 mg/dl
  2. ALT/AST < 3x upper limit of normal range
  3. Direct bilirubin <2.0 mg/dl
  4. Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea, pulse oxygen > 92% on room air, and DLCO > 40% (corrected for anemia if clinically appropriate)
  5. Left Ventricle Ejection Fraction (LVEF) ≥ 40% confirmed by ECHO/MUGA
• Bone marrow with ≥ 5% lymphoblasts
• Male or female age ≥ 18 years
• A ECOG Performance Status that is either 0 or 1
• No contraindications for leukapheresis.

Retreatment Inclusion Criteria

• Performance Status 0-1

• Adequate organ system function including:

  • Creatinine < 1.6 mg/dl
  • ALT/AST < 3x upper limit of normal
  • Total Bilirubin < 2.0 mg/dl
  • Must have a minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea, pulse oxygen > 92% on room air, and DLCO > 40% (corrected for anemia if clinically appropriate)
• Left Ventricular Ejection Fraction ≥ 40%
• No contraindications for leukapheresis (if required for retreatment)
• Gives voluntary informed consent for retreatment

Exclusion Criteria

• Isolated extramedullary disease relapse
• Active hepatitis B or active hepatitis C
• Class III/IV cardiovascular disability according to the New York Heart Association Classification
• HIV infection
• Active acute or chronic graft-versus-host disease (GVHD) or requirement of immunosuppressant medications for GVHD within 4 weeks of enrollment.
• Concurrent use of systemic steroids or chronic use of immunosuppressant medications. Recent or current use of inhaled steroids is not exclusionary. For additional details regarding use of steroid and immunosuppressant medications.
• Active CNS involvement by malignancy. Note: Patients with history of CNS disease that has been effectively treated will be eligible provided that treatment was >4 weeks before enrollment
• Pregnant or nursing (lactating) women, female study participants of reproductive potential must have a negative serum or urine pregnancy test within 48 hours before infusion
• Participation in a prior investigational study within 4 weeks prior to enrollment or longer if required by local regulation. Participation in non-therapeutic research studies is allowed.
• Patients with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system.

Retreatment Exclusion Criteria

• Pregnant or lactating women.
• Active hepatitis B or hepatitis C
• Concurrent use of systemic steroids or chronic use of immunosuppressant medications. Recent or current use of inhaled steroids is not exclusionary. For additional details regarding use of steroid or immunosuppressant medications.
• HIV infection
• Patients with active CNS involvement with malignancy. Patients with prior CNS disease that has been effectively treated will be eligible providing treatment was >4 weeks before enrollment on the retreatment cohort.
• Class III/IV cardiovascular disability according to the New York Heart Association Classification
• Patients with a known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system.

Contacts and Locations

Locations

United States, Pennsylvania

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19104

Sponsors and Collaborators

University of Pennsylvania

Investigators

• Principal Investigator: Noelle Frey, MD; Abramson Cancer Center at Penn Medicine

  Study Documents (Full-Text)

Documents provided by University of Pennsylvania:

Study Protocol and Statistical Analysis Plan  [PDF] April 14, 2017

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Frey NV, Shaw PA, Hexner EO, Pequignot E, Gill S, Luger SM, Mangan JK, Loren AW, Perl AE, Maude SL, Grupp SA, Shah NN, Gilmore J, Lacey SF, Melenhorst JJ, Levine BL, June CH, Porter DL. Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. J Clin Oncol. 2020 Feb 10;38(5):415-422. doi: 10.1200/JCO.19.01892. Epub 2019 Dec 9.

• Responsible Party: University of Pennsylvania
• ClinicalTrials.gov Identifier: NCT02030847
• Other Study ID Numbers: UPCC 21413, 818626
• First Posted: January 9, 2014
• Results First Posted: May 24, 2019
• Last Update Posted: August 30, 2019
• Last Verified: August 2019

Additional relevant MeSH terms:

Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphoid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases